{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-102489","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.957810+00:00","generated_at":"2026-05-15T13:39:41.776143+00:00","sec_items":["7.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Solid Biosciences reports positive interim SGT-003 data; microdystrophin expression 60% at Day 90, 91% at Day 360","bullets":["40 participants dosed; SGT-003 well tolerated with steroid-only immunomodulation regimen.","Day 90 biopsy (n=20): mean microdystrophin expression 60% (western blot), 63% positive fibers; 60% beta-sarcoglycan restoration.","Day 360 biopsy (n=3): microdystrophin expression 91% (western blot), 69% positive fibers; 69% beta-sarcoglycan restoration.","Biomarker improvements: CK -38%, ALT -43%, AST -30%, LDH -46%, eMHC -44% at Day 90.","FDA aligned on Phase 3 design; screening underway; first participant dosing expected Q1 2026; accelerated approval discussions planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-102489","json":"https://secwatch.observer/filing/0001193125-26-102489.json","markdown":"https://secwatch.observer/filing/0001193125-26-102489.md","text":"https://secwatch.observer/filing/0001193125-26-102489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526102489/0001193125-26-102489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526102489/sldb-20260311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:39:41.776143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}